SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Lunai Bioworks Inc. (LNAI) has a negative trailing P/E of -0.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -1,348.82%.
Criteria proven by this page:
- VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -0.1); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -1,348.82%).
- Trailing Earnings Yield -1,348.82% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
Overall SharesGrow Score: 10/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — LNAI
Valuation Multiples
P/E (TTM)-0.1
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio-0.69
P/S Ratio0.00
EV/EBITDA-1.2
Per Share Data
EPS (TTM)$-5.35
Book Value / Share$-0.58
Revenue / Share$0.00
FCF / Share$-0.24
Yields & Fair Value
Earnings Yield-1,348.82%
Dividend Yield0.00%
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2021 |
-0.4 |
0.00 |
0.06 |
0.00 |
- |
| 2022 |
-0.1 |
0.00 |
0.16 |
0.00 |
- |
| 2023 |
-0.3 |
0.00 |
0.28 |
0.00 |
- |
| 2024 |
-0.3 |
-0.01 |
0.17 |
0.00 |
- |
| 2025 |
-0.2 |
-0.01 |
-1.76 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2020 |
$-5.67 |
$0.00 |
$-26.72M |
- |
| 2021 |
$-21.60 |
$0.00 |
$-113.43M |
- |
| 2022 |
$-7.10 |
$0.00 |
$-39.68M |
- |
| 2023 |
$-9.10 |
$0.00 |
$-88.43M |
- |
| 2024 |
$-10.78 |
$0.00 |
$-178.01M |
- |
